Elaine Hurt

Company: AstraZeneca

Job title: Executive Director

Seminars:

Case Study: Utilizing Hindsight Following Progression of an ADC With a HER2 Target Into the Clinic 1:15 pm

Highlighting the target selection process and reasons behind the choice of pursuing HER2 Highlighting target and antibody considerations Emphasizing challenges and successes in the development of a HER2 targeting ADCRead more

day: Conference Day One

Panel Discussion: What Is the Next Generation of ADC Targets? 11:00 am

Discussing current developments in validate ADC targets, ADC and IO combination therapy for tumor eradication rather than temporary tumor regression Exploring novel targets with non-conventional (non-clathrin-mediated) internalization pathways; targets with expression in the tumor microenvironment e.g. angiogenic blood vessels Discovering the future of ADC targets that can internalize to intracellular space and by passing the…Read more

day: Conference Day One